top of page
top of about
GIAPREZA (ANGIOTENSIN II) INJECTION
In December 2017, GIAPREZA (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA mimics the body's endogenous angiotensin II peptide. This peptide is central to the
renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure.
Please see full GIAPREZA FDA prescribing information for additional safety information.